Just 800 of the 13,500 patients eligible to start receiving Wegovy, which can help obese people lose 15% of their body weight ...

One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

PS makes wellness more accessible through real-life stories, first-person perspectives, and expert-backed information. Our ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And ...

As obesity clinical trials evolve, there is a growing emphasis on how decentralisation and new technologies can play a role.

Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s ...

Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...

Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme. View on ...